EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Quantification of lenalidomide and pomalidomide enantiomers in multiple myeloma patients: An exploratory study

Gyan Vardhan, Vikas Kumar, Ashish Kumar, Uttam Kumar Nath, Shailendra Handu, Puneet Dhamija

Indian Journal of Pharmacology · 2026-11 · 58 (6) · 784-790

DOI: 10.4103/ijp.ijp_219_26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Pharmacology, online erschienen am 02.11.2026. Verfasst von Gyan Vardhan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India. Hauptthemen laut MEDLINE: Multiple Myeloma, Thalidomide, Lenalidomide. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Multiple myeloma (MM) is a malignant plasma cell disorder representing 1.8% of all cancers. Immunomodulatory drugs such as lenalidomide (LND) and pomalidomide (PMD) are crucial for treating MM. This study developed and validated a novel chiral stationary phase high-performance liquid chromatography (CSP-HPLC) method to quantify LND and PMD enantiomers in human plasma. METHODOLOGY: The study included 12 MM patients (6 on LND, 6 on PMD) in their second chemotherapy cycle. Blood samples were collected for trough and crest levels. The CSP-HPLC method successfully separated and quantified the enantiomers of both drugs. RESULTS: For LND, the S-(−) enantiomer showed mean trough and crest concentrations of 11.98 ng/mL and 211.44 ng/mL, respectively. The R-(+) enantiomer had mean trough and crest concentrations of 11.13 ng/mL and 199.86 ng/mL. For PMD, enantiomer-I showed mean trough and crest concentrations of 1.68 ng/mL and 71.45 ng/mL, while enantiomer-II had 1.06 ng/mL and 69.54 ng/mL, respectively. CONCLUSION: The study demonstrated that the S-enantiomer of LND and enantiomer-I of PMD had slightly higher plasma concentrations and potentially greater antimyeloma activity. These findings provide a basis for developing enantiomeric compounds of LND and PMD, which could lead to more effective and safer treatments for MM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaThalidomideLenalidomideHumansStereoisomerismChromatography, High Pressure LiquidFemaleMaleMiddle Aged

Stichwörter der Autor:innen

Enantiomershigh-performance liquid chromatographylenalidomidemultiple myelomapomalidomide

Substanzen

pomalidomideThalidomideLenalidomide

Autor:innen und Institutionen

  • Department of Pharmacology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
  • Department of Pharmacology, All India Institute of Medical Sciences, Bathinda, Punjab, India.
  • Department of Medical Oncology Haematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.

Zitieren

APA

Vardhan, G., Kumar, V., Kumar, A., Nath, U. K., Handu, S., & Dhamija, P. (2026). Quantification of lenalidomide and pomalidomide enantiomers in multiple myeloma patients: An exploratory study. Indian Journal of Pharmacology, 58(6), 784-790. https://doi.org/10.4103/ijp.ijp_219_26

Vancouver

Vardhan G, Kumar V, Kumar A, Nath UK, Handu S, Dhamija P. Quantification of lenalidomide and pomalidomide enantiomers in multiple myeloma patients: An exploratory study. Indian Journal of Pharmacology. 2026;58(6):784-790. doi:10.4103/ijp.ijp_219_26

BibTeX
@article{Vardhan2026,
  author = {Vardhan, Gyan and Kumar, Vikas and Kumar, Ashish and Nath, Uttam Kumar and Handu, Shailendra and Dhamija, Puneet},
  title = {Quantification of lenalidomide and pomalidomide enantiomers in multiple myeloma patients: An exploratory study},
  journal = {Indian Journal of Pharmacology},
  year = {2026},
  volume = {58},
  number = {6},
  pages = {784--790},
  doi = {10.4103/ijp.ijp_219_26}
}
Kostenlos starten →